What is it about?
The article shows the development of two mRNA vaccine constructs targeting the Ilesha virus (ILEV), an arthropod-borne virus from the Orthobunyavirus genus, associated with febrile illness, meningoencephalitis, and hemorrhagic fever. Using immunoinformatics and bioinformatics tools, researchers identified antigenic viral proteins (RNA polymerase, M polyprotein, and nucleoprotein) and predicted cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes. Epitopes were evaluated for antigenicity, allergenicity, toxicity, and cytokine induction potential, and the most promising ones were selected for vaccine construction.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
The proposed mRNA vaccine constructs are promising candidates for preventing Ilesha virus infections. At present, there are no vaccines or antiviral therapies against the virus.
Perspectives
Two multi-epitope mRNA vaccine constructs were designed, each containing nine epitopes (three CTL, three HTL, and three B-cell epitopes), adjuvants, MHC class I-targeting domains, untranslated regions (UTRs), and linkers for efficient expression and immune activation. Both constructs demonstrated high antigenicity, non-toxicity, non-allergenicity, favorable physicochemical properties, and structural stability. Molecular docking with Toll-like receptors (TLR-3 and TLR-4) showed strong binding affinities, supporting their potential to elicit robust immune responses.
Tajudeen Oladunni GANIYU
Fountain University
Read the Original
This page is a summary of: Immunoinformatics-Based strategies for mRNA vaccine development against ilesha virus, In Silico Research in Biomedicine, January 2025, Elsevier,
DOI: 10.1016/j.insi.2025.100046.
You can read the full text:
Contributors
The following have contributed to this page
